<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233141</url>
  </required_header>
  <id_info>
    <org_study_id>VICLI-2010</org_study_id>
    <nct_id>NCT01233141</nct_id>
  </id_info>
  <brief_title>Viennese Registry on Patients With Chronic Critical Limb Ischemia</brief_title>
  <official_title>Phase IV Hospital Based Registry to Explore the Outcome of Chronic Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale of this study is to establish a registry to detect and follow patients with CLI&#xD;
      treated in Vienna. The Vienna CLI registry is meant to document the incidence, prevalence,&#xD;
      and actual outcome of CLI patients in a real world setting and should serve as a tool for the&#xD;
      evaluation of medical, endovascular and surgical interventions. It will help determining the&#xD;
      prognosis of individual patients and have impact on economic and political decisions in&#xD;
      Vienna concerning this disease and the related costs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective observational cohort study including consecutive patients with CLI. The&#xD;
      study will be initiated as a single center evaluation and is intended to be step-wise&#xD;
      expanded to a Vienna-wide systematic survey. The study will include patients with chronic&#xD;
      critical limb ischemia and ischemic ulcerations as defined by Fontaine stage IV or Rutherford&#xD;
      stages 5 &amp; 6. The study will include all patients presenting with CLI to the participating&#xD;
      centers including inpatients and outpatients.&#xD;
&#xD;
      Patients will be followed up 1 month, 3 months, 6 months, 12 months and then every 6 months.&#xD;
      The study will be continued at least until the 5 year data of the last included patient are&#xD;
      available.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ipsilateral amputation rate</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>stroke</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chronic (&gt; 2 Weeks) Critical Ischemia With Skin Defect in Lower Limbs</condition>
  <arm_group>
    <arm_group_label>one group only</arm_group_label>
    <description>all participants</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, plasma, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        tertiary care centre&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic (&gt; 2 weeks) critical limb ischemia in one or both of the lower extremities&#xD;
             with necrosis and/or gangrene in the limb (peripheral artery disease IV according to&#xD;
             Fontaine's classification or Rutherford stage 5 &amp; 6) of whatever genesis&#xD;
             (atherosclerotic, aneurysmatic, embolic, inflammatory)&#xD;
&#xD;
          -  ankle/brachial index &lt; 0.4 or toe pressure &lt; 30 mmHg&#xD;
&#xD;
          -  Ability to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  o Ulceration exclusively due to nonvascular causes like neuropathy (without coexisting&#xD;
             hemodynamic impairment as defined above) or venous ulceration (without coexisting&#xD;
             arterial impairment as defined above)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Silvia Charwat-Resl, MD</last_name>
    <phone>+43140400</phone>
    <phone_ext>4670</phone_ext>
    <email>silvia.charwat@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Schillinger, MD</last_name>
    <phone>+4340400</phone>
    <phone_ext>4670</phone_ext>
    <email>martin.schillinger@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Charwat-Resl, MD</last_name>
      <phone>+43140400</phone>
      <phone_ext>4670</phone_ext>
      <email>silvia.charwat@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Silvia Charwat-Resl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <last_update_submitted>July 27, 2011</last_update_submitted>
  <last_update_submitted_qc>July 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Silvia Charwat</name_title>
    <organization>Medical University of Vienna</organization>
  </responsible_party>
  <keyword>peripheral artery disease stage IV (Fontaine's classification) or stage 5 and 6 (Rutherford's classification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

